Clinical Trials Logo

Adult Acute Myeloid Leukemia clinical trials

View clinical trials related to Adult Acute Myeloid Leukemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06045819 Not yet recruiting - Clinical trials for Adult Acute Myeloid Leukemia

Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)

Start date: January 2024
Phase:
Study type: Observational

Background: In combination with hypomethylating drugs, venetoclax has recently changed the therapeutic management of patients with newly diagnosed acute myeloid leukemia (AML) for whom standard induction chemotherapy was not an option. Over and above the clinical benefits of this combination, the data show that more than half the patients did not show remission criteria, even after the first month's exposure to venetoclax. Hypothesis: To compare the mean residual venetoclax plasma concentrations obtained in patients who went into complete composite remission versus those who did not go into remission at the end of the first cycle of venetoclax + azacitidine treatment. Method: According to the French law, this is a multicenter, non-comparative, open-label, single-arm, interventional study with minimal risks and constraints. Selection, information and inclusion will concern adult patients (≥60 years) with a confirmed diagnosis of AML according to ELN 2022 guidelines. Included patients will be treated as standard care with a combination of venetoclax+azacitidine. This research protocol will not modify their usual care.

NCT ID: NCT03283228 Not yet recruiting - Clinical trials for Adult Acute Myeloid Leukemia

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Start date: December 1, 2017
Phase: N/A
Study type: Observational

1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.